Article

FluBlok, a recombinant hemagglutinin influenza vaccine.

Protein Sciences Corporation, 1000 Research Parkway, Meriden, CT 06450, USA.
Influenza and Other Respiratory Viruses (Impact Factor: 1.9). 12/2008; 2(6):211-9. DOI: 10.1111/j.1750-2659.2008.00053.x
Source: PubMed

ABSTRACT FluBlok, a recombinant trivalent hemagglutinin (HA) vaccine produced in insect cell culture using the baculovirus expression system, provides an attractive alternative to the current egg-based trivalent inactivated influenza vaccine (TIV) manufacturing process. FluBlok contains three times more HA than TIV and does not contain egg-protein or preservatives. This review discusses the four main clinical studies that were used to support licensure of FluBlok under the 'Accelerated Approval' mechanism in the United States.

Download full-text

Full-text

Available from: Peter Patriarca, Feb 16, 2015
0 Followers
 · 
145 Views